Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine

We summarised four pivotal Randomised Controlled Trials (RCTs) with antirheumatic drugs on the secondary prevention of cardiovascular events. The favourable effects of canakinumab and colchicine confirm (low-grade) inflammation as an independent risk factor for cardiovascular events. While colchicin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lems, Willem, Boers, Maarten, van Vollenhoven, Ronald F, Nurmohamed, Mike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Treatments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970260/
https://www.ncbi.nlm.nih.gov/pubmed/33727219
http://dx.doi.org/10.1136/rmdopen-2020-001560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970260/
https://www.ncbi.nlm.nih.gov/pubmed/33727219
http://dx.doi.org/10.1136/rmdopen-2020-001560

Ejemplares similares